SCHEMBL19465019

SCHEMBL19465019

CNC(=O)C(=O)CC(=O)c1ccncc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLOD2 O00469 4/20 0.56
▸ PLOD3 O60568 3/20 0.56
▸ PLOD1 Q02809 3/20 0.56
▸ CYP1A2 P05177 2/20 0.56
▸ CYP3A4 P08684 2/20 0.56
▸ CYP2D6 P10635 2/20 0.56
▸ CYP2C19 P33261 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ HIF1A Q16665 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.46
▸ MPO P05164 1/20 0.46
▸ ADORA3 P0DMS8 1/20 0.46
▸ CYP2A6 P11509 1/20 0.46
▸ NAPRT Q6XQN6 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ PTPN1 P18031 1/20 0.41
▸ ERCC5 P28715 1/20 0.41
▸ FEN1 P39748 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160670 0.81 PLOD2 (0.60) PLOD2PLOD3PLOD1CYP1A2CYP3A4
SCHEMBL19459868 0.81 CYP3A4 (0.51) PLOD2PLOD3PLOD1CYP1A2CYP3A4
SCHEMBL10948430 0.80 PLOD2 (0.83) PLOD2PLOD3PLOD1CYP1A2CYP3A4
SCHEMBL17179998 0.79 PLOD2 (0.68) PLOD2PLOD3PLOD1CYP1A2CYP3A4
SCHEMBL1062957 0.78 PLOD2 (0.56) PLOD2PLOD3PLOD1CYP1A2CYP3A4
SCHEMBL3108729 0.76 PLOD2 (0.64) PLOD2PLOD3PLOD1CYP1A2CYP3A4
SCHEMBL16373727 0.75 CYP2C19 (0.57) PLOD2PLOD3PLOD1CYP1A2CYP3A4
SCHEMBL28972977 0.75 PLOD2 (0.62) PLOD2PLOD3PLOD1CYP1A2CYP3A4
SCHEMBL29664616 0.75 PLOD2 (0.62) PLOD2PLOD3PLOD1CYP1A2CYP3A4
SCHEMBL200805 0.74 PLOD2 (0.73) PLOD2PLOD3PLOD1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790197-B2 Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) 2017-10-17 — — US disclosed
Send feedback